The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G02 | Other gynecologicals | |
| 3 | G02C | Other gynecologicals | |
| 4 | G02CX | Other gynecologicals |
| Code | Title | |
|---|---|---|
| G02CX01 | Atosiban | |
| G02CX02 | ||
| G02CX03 | ||
| G02CX04 | ||
| G02CX05 | ||
| G02CX06 |
| Active Ingredient | Description | |
|---|---|---|
| Atosiban |
Atosiban is a synthetic peptide which is a competitive antagonist of human oxytocin at receptor level. In human pre-term labour, atosiban at the recommended dosage antagonises uterine contractions and induces uterine quiescence. |
|
| Fezolinetant |
Fezolinetant is a non-hormonal selective neurokinin 3 (NK3) receptor antagonist. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus. |
|
| Flibanserin |
Flibanserin is a multifunctional serotonin agonist and antagonist used for the treatment of premenopausal women with hypoactive sexual desire disorder. In vitro, flibanserin acts as an agonist on 5-HT1A receptors and an antagonist on 5-HT2A receptors. It also has moderate antagonist activities at the 5-HT2B, 5-HT2C, and dopamine D4 receptors. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ADDYI Film coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| Tractocile 7.5 mg/ml Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| TRACTOCILE Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VEOZA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
